We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
2010 ->48 hours of cisatracurium reduced 90-day mortality in patients with early, severe ARDS.
- Authors
Sevransky, Jonathan
- Abstract
Question: In patients with early, severe acute respiratory distress syndrome (ARDS), does short-term treatment with cisatracurium besylate, a neuromuscular-blocking agent, improve clinical outcomes? Methods Design Randomized placebo-controlled trial (ARDS et Curarisation Systematique [ACURASYS] study). ClinicalTrials.gov NCT00299650. Allocation Concealed.* Blinding Blinded (patients, clinicians, outcome assessors, monitors, and data analysts).* Follow-up period 90 days. Setting 20 intensive care units (ICUs) in France. Patients 340 patients (mean age 58 y) who were receiving endotracheal mechanical ventilation for acute hypoxemic respiratory failure and had all of the following for >48 hours: PaO[sub 2]/FIO[sub 2] <>150 with ventilator set to a positive end-expiratory pressure >5 cm H[sub 2]0 and tidal volume of 6 to 8 mL/kg predicted body weight; bilateral pulmonary infiltrates consistent with edema; and no clinical evidence of left atrial hypertension. Exclusion criteria included pregnancy, increased intracranial pressure, severe chronic respiratory disease (chronic oxygen use or home ventilation), and severe chronic liver disease. Intervention Intravenous cisatracurium besylate (n =>178) or placebo (n =>162). After the Ramsay sedation score reached 6 (no response to glabellar tap) and ventilator settings were adjusted, a rapid infusion of 15 mg was administered, followed by a continuous infusion of 37.5 mg/h for 48 hours. Outcomes Primary outcome was 90-day mortality (before discharge and within 90 d after enrollment). Secondary outcomes included ventilator-free days, days without organ failure (cardiovascular, renal, hepatic, or coagulation abnormalities), barotrauma, and ICU-acquired paresis. Patient follow-up 99.7% (intention-to-treat analysis). Main results Patients who received cisatracurium had a lower adjusted risk for mortality at 90 days and lower risk for barotrauma (mostly pneumothorax) than those who received placebo (Table). The groups had a similar risk for ICU-acquired paresis at 28 days and ICU discharge; however, <>60% of patients were included in these analyses (29% [28/96] vs 32% [25/77], P =>0.64, and 36% [40/112] vs 31% [28/89], P =>0.51, respectively). At 28 days, the cisatracurium group had more ventilator-free days (mean 10.6 vs 8.5, P =>0.04) and days without organ failure (mean 15.8 vs 12.2, P =>0.01). Conclusion In patients with early, severe acute respiratory distress syndrome, short-term cisatracurium treatment reduced mortality at 90 days.
- Publication
ACP Journal Club, 2011, Vol 154, Issue 1, p2
- ISSN
1056-8751
- Publication type
Article